The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of 
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of 
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients

Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot. Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. The study aimed to compare th...

Full description

Bibliographic Details
Main Authors: Yuxiang MA, Yan HUANG, Hongyun ZHAO, Junling LIU, Likun CHEN, Haiying WU, Ningning ZHOU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2013-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Gefitinib
Erlotinib
Lung neoplasms
Cost-effectiveness analysis
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2013.04.06

Similar Items

Similar Items